The aim of the study is to confirm, whether the MER® stent can be used, without limitations, for the endovascular carotid stenosis treatment in daily clinical practice. Eligible patients will undergo the procedure of the common or internal carotid artery stenting using MER® with proximal or distal neuroprotection.
MER® stent will be implanted in eligible patients with common and internal carotid stenosis after an informed consent. Potential benefit of the MER® stent implantation will be evaluated based on angiography and duplex Doppler ultrasound examination. Follow ups are scheduled at 30 days, 6 and 12 months after index procedure. Except for clinical follow up patients will undergo carotid vessels ultrasound examination after 6 and 12 months. In case of an emergency visit, caused by the Serious Adverse Event, Patient will undergo: neurological and cardiac evaluation as well as carotid vessels USG examination and extended CT or MRI scans. In general, all procedures in the study will follow the local standard of care. The type of devices used during the angioplasty (including the MER® stents) will not differ from the devices used in the usual clinical practice in the hospital. DAPT and other medical therapy will be consistent with the rules of the Polish and European Society of Cardiology.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
carotid artery stenting
Małopolskie Centrum Sercowo-Naczyniowe PAKS American Heart of Poland S.A., Oddział Chirurgii naczyniowej
Chrzanów, Poland
Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Uniwersytetu Medycznego w Katowicach, Oddział Chirurgii Ogólnej, Naczyń, Angiologii i Flebologii
Katowice, Poland
Oddział Kliniczny Chorób Serca i Naczyń Krakowski Szpital Specjalistyczny im. Jana Pawła II
Krakow, Poland
Centrum Interwencyjnego Leczenia Udaru i Chorób Naczyniowych Mózgu Instytut Psychiatrii i Neurologii
Stroke within 30 days after the procedure
Stroke within 30 days after the procedure
Time frame: 30 days
MAE
compound Major Adverse Events (death, stroke, heart attack) within 30 days after the procedure
Time frame: 30 days
MAE
compound Major Adverse Events (death, stroke, heart attack) within 365 days after the procedure. Restenosis (%DS ≥50%) within 365 days.
Time frame: 365 days
Target vessel revascularization within 365 days
Target vessel revascularization within 365 days
Time frame: 365 days
Procedure success
Procedure success (with residual stenosis ≤30%)
Time frame: 365 days
SADE
Serious Adverse Device Effect
Time frame: 365 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Warsaw, Poland